Company Overview
| Stock Name | Int Medical |
|---|---|
| Stock Code | 01501 |
| Company Full Name | To be extracted |
| Industry | 医疗器械 |
| Principal Activities | 我們是中國領先的心內介入器械製造商。主要產品包括球囊擴張壓力泵、導管鞘套裝、造影導絲、動脈壓迫止血帶、Y型連接器套裝、壓力延長管、三通旋塞及造影導管,主要用於心血管介入手術(特別是PCI手術)。 |
| Listing Date | 2019-11-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市嘉定區金園一路925號2幢 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座31樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | kdl-int.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 20.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 200 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2019-10-28 to 2019-10-31 |
| Global Offering Shares | 40,000,000 shares |
| HK Public Offer Shares (Initial) | 4,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 20,000lots (Pool A10,000lots,Pool B10,000lots) |
| International Placing Shares (Initial) | 36,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 160,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 28.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 832,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 4,160 |
| 2 lots | 400 | HK$ 8,320 |
| 3 lots | 600 | HK$ 12,480 |
| 4 lots | 800 | HK$ 16,640 |
| 5 lots | 1,000 | HK$ 20,800 |
| 6 lots | 1,200 | HK$ 24,960 |
| 7 lots | 1,400 | HK$ 29,120 |
| 8 lots | 1,600 | HK$ 33,280 |
| 9 lots | 1,800 | HK$ 37,440 |
| 10 lots | 2,000 | HK$ 41,600 |
| 15 lots | 3,000 | HK$ 62,400 |
| 20 lots | 4,000 | HK$ 83,200 |
| 25 lots | 5,000 | HK$ 104,000 |
| 30 lots | 6,000 | HK$ 124,800 |
| 35 lots | 7,000 | HK$ 145,600 |
| 40 lots | 8,000 | HK$ 166,400 |
| 45 lots | 9,000 | HK$ 187,200 |
| 50 lots | 10,000 | HK$ 208,000 |
| 100 lots | 20,000 | HK$ 416,000 |
| 150 lots | 30,000 | HK$ 624,000 |
| 200 lots | 40,000 | HK$ 832,000 |
| 250 lots | 50,000 | HK$ 1,040,000 |
| 300 lots | 60,000 | HK$ 1,248,000 |
| 350 lots | 70,000 | HK$ 1,456,000 |
| 400 lots | 80,000 | HK$ 1,664,000 |
| 450 lots | 90,000 | HK$ 1,872,000 |
| 500 lots | 100,000 | HK$ 2,080,000 |
| 750 lots | 150,000 | HK$ 3,120,000 |
| 1,000 lots | 200,000 | HK$ 4,160,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,250 lots | 250,000 | HK$ 5,200,000 |
| 1,500 lots | 300,000 | HK$ 6,240,000 |
| 1,750 lots | 350,000 | HK$ 7,280,000 |
| 2,000 lots | 400,000 | HK$ 8,320,000 |
| 2,250 lots | 450,000 | HK$ 9,360,000 |
| 2,500 lots | 500,000 | HK$ 10,400,000 |
| 3,000 lots | 600,000 | HK$ 12,480,000 |
| 3,500 lots | 700,000 | HK$ 14,560,000 |
| 4,000 lots | 800,000 | HK$ 16,640,000 |
| 4,500 lots | 900,000 | HK$ 18,720,000 |
| 5,000 lots | 1,000,000 | HK$ 20,800,000 |
| 7,500 lots | 1,500,000 | HK$ 31,200,000 |
| 10,000 lots | 2,000,000 | HK$ 41,600,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 6.81B |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +42% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 3,272,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币58.2百万元 |
| Period-End Cash Balance | 人民币298.2百万元 |
| Listing Expenses | ~HK$ 73,500,000 |
| Listing Expenses / Funds Raised | ~8.83% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Profit for the year | 34,001 | 40,770 | 58,236 |
Balance Sheet
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Cash and cash equivalents | 64,445 | 146,702 | 298,164 |
| Trade and bills receivables | 66,295 | 11,375 | 7,085 |
| Inventories | 16,146 | 29,468 | 39,015 |
| Total current assets | 148,610 | 189,683 | 347,630 |
| Total assets | 186,092 | 232,456 | 482,040 |
| Total current liabilities | 20,214 | 27,234 | 42,734 |
| Total liabilities | 26,648 | 32,242 | 100,730 |
| Total equity | 159,444 | 200,214 | 381,310 |
| Equity attributable to owners | 159,444 | 200,214 | 372,025 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 | 2019-04 |
|---|---|---|---|---|
| Net cash from operating activities | 38,910 | 39,324 | 66,492 | |
| Net cash from investing activities | -12,883 | 45,675 | -39,584 | |
| Net cash from financing activities | -12,800 | 0 | 121,896 | |
| Net increase in cash | 13,227 | 84,999 | 148,804 | |
| Purchase of PP&E | -12,333 | -12,180 | -34,554 | -10,877 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 27.0 |
|---|---|
| First Day Open | HK$ 27.0 |
| First Day Change | 29.81% |
| First Day Volume | 32637500.0 |
| First Day Turnover | 899357000.0 |
| Use of Proceeds | 1、凈所得款項中的約34.1%或258.5百萬港元,擬用于建設位于上海市嘉定區的研發中心及其他設施;
2、凈所得款項中的約14.4%或109.2百萬港元,將用于開發現有管線產品并將其商業化,以及進一步拓展其產品供應;
3、凈所得款項中的約13.8%或104.6百萬港元,將用于購買額外生產設備并替換現有生產設備及將生產線自動化;
4、凈所得款項中的約8.7%或65.9百萬港元,將用于擴大其分銷網絡及覆蓋范圍、與當地分銷商的合作及加大營銷力度;
5、凈所得款項中的約19.6%或148.6百萬港元,將用于為潛在戰略投資(包括收購、合伙及外部授權)提供資金;
6、凈所得款項中的約9.4%或71.2百萬港元,將用于一般企業用途和為其營運資金提供資金。 |
Underwriting Syndicate
Sole Sponsor (1)
BOCOM International (Asia) Limited CE API271
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Worldwide Healthcare Trust PLC | 235,306,240 HKD | — | 28.28% | — | 6 months | 2020-05-08 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 梁棟科 | — |
| Company Secretary | 宋媛、梁瑞冰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 康德萊及其控股方合共持股26.79%;寧波懷格泰益持股15.75%;梁棟科持股5.96%;OrbiMed Capital LLC持股7.07%(H股基石投资) |
|---|




